linjc16/ctgov huggingface dataset:
Evaluation of the Triage Risk Screening Tool

Study Overview
=================
Brief Summary
-----------------
This study tried to describe diagnostic properties of TRST completed by an emergency doctor, for screening process for fragility of elderly subjects admitted at the accident and emergency department.

Detailed Description
-----------------
A constant increase of emergencies admission of elderly subjects is registered. The current problem is the identification and early screening of these patients upon admission at the accident and emergency department for early tracking in geriatric network. This early assessment could allow a shorter waiting time, a better orientation of patients and a decrease in the number of re-hospitalization. There are many screening process for fragility tests but there seem to be nonspecifically. The advantage of TRST is its simplicity and speed of filling. In 2015, Duc et al. have found that TRST may be a screening instrument for elderly subject and is going to require geriatric mobile team (GMT) for evaluation. Unfortunately, the threshold may be too sensitive and GMT solicitation is too high.

Official Title
-----------------
Evaluation of the Triage Risk Screening Tool (TRST) as Screening Instrument Elderly Subject Fragility at the Accident and Emergency Department

Conditions
-----------------
Elderly Subject Fragility

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are more than 75 years old Admitted to the emergency department for medical or surgical reason Admitted from Monday to Friday (8h30 AM- 6h PM) Exclusion Criteria: Patient with specific care (vital emergency, urgent surgery) Patient or his support person opposing the use of data

Ages Eligible for Study
-----------------
Minimum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TRST-U | Triage Risk Screening Tool completed by an emergency doctor | Day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TRST-G | Triage Risk Screening Tool completed by a geriatrician | Day 1 | 
| SEGA instrument | Evaluation of TRST versus SEGA instrument (gold standard) | Day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Screening instrument
Enhancement of Brown Adipose Tissue Function Via Chronic Pharmacological Treatment

Study Overview
=================
Brief Summary
-----------------
Obesity is epidemic in Australia, and current preventative strategies have had limited success in alleviating this health crisis. While numerous options are available for treatment of obesity, most do not result in sustained weight reduction. Obesity results from an imbalance between energy intake and expenditure, therefore new methods that correct this imbalance are essential for effective long-term treatment. Rodent studies show that brown adipose tissue (BAT) can burn more energy than any other tissue in the body, therefore targeting BAT to increase its activity (energy burning rate) and quantity in humans is potentially a powerful tool for the treatment of obesity and related diseases. BAT has only recently been irrefutably identified in adult humans therefore little is known about how it functions in humans.

Official Title
-----------------
Enhancement of Brown Adipose Tissue Function Via Chronic Pharmacological Treatment

Conditions
-----------------
Obesity, Type 2 Diabetes, Cardiovascular Disease

Intervention / Treatment
-----------------
* Drug: Placebo
* Drug: Ephedrine, pioglitazone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males aged 19 - 35 years Free of overt coronary disease (on history, medical examination and ECG) Unmedicated No major illness BMI <27 kg/m2 Exclusion Criteria: Unable to give informed consent Smokers Participant in research projects involving ionising radiation within the past 5 years. Claustrophobia Fasting plasma glucose > 6.0 mmol/L

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br>lactose powder in equivalent capsule | Drug: Placebo<br> <br> |
| Experimental: Drug treatment<br>sympathetic agonist and thiazolidinedione | Drug: Ephedrine, pioglitazone<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| brown adipose tissue activity | measured via PET-CT | 3 years |
Using Three Different Final Irrigants and Showing Their Effects on the Success of Revascularization

Study Overview
=================
Brief Summary
-----------------
this study will assess different irrigating materials on the success revascularization of necrotic mature teeth associated with PRF.

Detailed Description
-----------------
Nano-propolis and Propolis will be used as final endodontic irrigants and will be compared to saline in Revascularization of necrotic mature teeth.

Official Title
-----------------
Assessment of Implementing Nano-technology in the Irrigation Protocol of One Step Revascularization For Necrotic Mature Teeth

Conditions
-----------------
Post-operative Pain

Intervention / Treatment
-----------------
* Drug: Propolis
* Drug: Nano-propolis
* Drug: saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: mature teeth. teeth with periapical periodontitis. Maxillary anterior teeth Patients should be free from any systemic disease Patients who will agree to the consent and will commit to follow-up period. Exclusion Criteria: Patients with immature roots. Patients with any systemic disease that may affect normal healing. Patients with swelling. .Pregnant females. .Patients who could/would not participate in a 1-year follow-up. .Patients with fistula. .Patients with old age. .Teeth with periodontal involvement. .Teeth with vertical root fractures. .Non-restorable teeth.

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: propolis<br>natural antibacterial, anti-inflammatory irrigation solution | Drug: Propolis<br>* Using propolis as a final irrigation in revascularization<br>* Other names: natural irrigant;|
| Experimental: Nano-propolis<br>natural antibacterial, anti-inflammatory irrigation solution | Drug: Nano-propolis<br>* Using Nano-propolis as a final irrigation in revasculariztion<br>* Other names: Natural irrigant;|
| Active Comparator: saline<br>sodium chloride irrigation solution | Drug: saline<br>* Using saline as a final irrigation in revasculariztion<br>* Other names: sodium chloride;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| post-operative pain: Visual analogue scale | post-operative pain evaluated using Visual analogue scale , 0 no pain, 10 severe pain. | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| periapical healing | evaluated radiographically | 1 year | 
| sensitivity | electric pulp tester | 1 year | 
| survival | clinical evaluation | 1 year |
Glasgow Asthma and Allergy Study

Study Overview
=================
Brief Summary
-----------------
In the past, doctors separated people with asthma into two groups, those with allergic asthma (about 2/3rds of people) and those with non-allergic asthma. These labels are not much used now as the treatments for all people with asthma don't depend on this classification. However, new treatments for asthma may become available and the classification may again become important. It could be useful for clinicians to know how to identify which patients are likely to benefit from particular treatments. Additionally, some new blood tests are becoming available and some of these might help to categorise the type of asthma people have. What the study hopes to do is to identify patient features which make a diagnosis of allergic asthma more likely and to see which new blood tests are most likely to be helpful in confirming this diagnosis.

Official Title
-----------------
Cross Sectional Study to Evaluate and Associate Clinical and Laboratory Features of People With Allergic and Non-allergic Asthma

Conditions
-----------------
Asthma, Allergy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female patients aged 18 years old and over with a diagnosis of asthma and having received at least two prescriptions for any asthma medication in the last 12 months, who have signed an informed consent form prior to initiation of any study-related procedure Exclusion Criteria: under 18 years current smokers unwilling or unable to give informed consent a clinical diagnosis of COPD a history of anaphylaxis (skin prick test) participated in any clinical study in the last 12 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| General asthma population<br>People with asthma, aged 18 years and over, non smoker, all severities of disease, regardless of treatment, broad inclusion and few exclusion criteria. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum periostin level | This is a cross sectional study. Participants will be assessed and tests conducted at a single visit | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| skin prick test |  | 1 day | 
| Serum total IgE |  | 1 day | 
| Blood eosinophil count |  | 1 day | 
| Blood neutrophil count |  | 1 day | 
| Blood CD4 cells that are positive for CRTh2 |  | 1 day | 
| Blood eosinophils expressing CRTh2 |  | 1 day | 
| Spirometry |  | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diagnosis, Asthma, Allergy, Correlation study
LUX Lung Special Access Scheme Australia Named Patient Use (NPU)

Study Overview
=================
Brief Summary
-----------------
The program will provide early access to the investigational drug BIBW 2992 to treat patients with advanced NSCLC who have failed at least 12 weeks on erlotinib or gefitinib. The Compassionate Use Programme will also provide additional safety and efficacy information on BIBW 2992 use. Named Patient Use (NPU)

Official Title
-----------------
Expanded Access Program BIBW 2992 for Non Small Cell Lung Cancer ( NSCLC) Last Line Treatment

Conditions
-----------------
Carcinoma, Non-Small-Cell Lung

Intervention / Treatment
-----------------
* Drug: BIBW 2992


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Patients with pathologic confirmation of adenocarcinoma of the lung Stage IIIB with pleural effusion or Stage IV Exclusion criteria: Brain metastases which are symptomatic; patients with treated, asymptomatic brain metastases are eligible with stable brain disease for at least four 4 weeks without the requirement for steroids or anti epileptic therapy Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom as judged by the investigator. Patients who have any other life-threatening illness or organ system dysfunction, which in the opinion of the investigator, would either compromise patient safety or interfere with the evaluation of the safety of the test drug History of cardiac disease that is clinically significant, as judged by the investigator or uncontrolled cardiac disease (including congestive heart failure, angina, myocardial infarction, arrhythmia, including New York Heart Association (NYHA) functional classification of 3) Cardiac left ventricular function with resting ejection fraction of less than 50% Bilirubin 1.5 mg / dl (26 mol / L, SI unit equivalent) Aspartate amino transferase (AST) or alanine amino transferase (ALT) three times the upper limit of normal (if related to liver metastases five times the upper limit of normal) Serum creatinine 1.5 times of the upper normal limit or calculated/measured creatine clearance 45ml/min Women of child-bearing potential or men who are able to father a child unwilling to use a medically acceptable method of contraception during the trial Pregnancy or breast feeding Patients unable to comply with the protocol Patients with known HIV, active hepatitis B or active hepatitis C Pre-existing Interstitial Lung Disease (ILD) Requirement for treatment with any of the prohibited concomitant medications listed in Section 4.2.2.1. Patients already pre-treated with BIBW 2992

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: BIBW 2992|tablets|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Bilateral Cochlear Implant Benefit in Young Children

Study Overview
=================
Brief Summary
-----------------
The primary purpose of this study is to track patient outcomes for bilateral cochlear implant recipients in a cohort of 60 children, ages 12 to 36 months at time of surgery, who receive two implants in the same operation or in two different surgeries with the initial fitting of the devices separated by no more than six months.

Official Title
-----------------
Development of Auditory Skills in Young Deaf Children With Bilateral Cochlear Implants

Conditions
-----------------
Hearing Loss

Intervention / Treatment
-----------------
* Device: HiResolution Bionic Ear System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Profound bilateral hearing loss Have independently elected to undergo bilateral implantation of Advanced Bionics HiResolution Bionic Ear System Age at implant: 12-36 months No previous cochlear implant use English as the primary language spoken in the home Parental willingness to follow study protocol Exclusion Criteria: Deafness secondary to meningitis Presence of other conditions that could affect study participation

Ages Eligible for Study
-----------------
Minimum Age: 12 Months
Maximum Age: 36 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: HiResolution Bionic Ear System|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of Speech Perception Skills |  | Various time points | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Health-Related Quality of Life and Assessment of Communicative Performance |  | Various time points |
The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study

Study Overview
=================
Brief Summary
-----------------
To examine the current disease progression of PDP, the clinical, economic, and humanistic impact of anti-psychotic therapy in the management of the condition in real-world settings, and the burden of the condition on patients and their caregivers

Official Title
-----------------
Management of Parkinson's Disease Psychosis in Actual Practice (The INSYTE Study)

Conditions
-----------------
Parkinson Disease Psychosis

Intervention / Treatment
-----------------
* Other: Real-world, non-interventional


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult males and females ≥ 18 with PDP Ability to understand and read English Patient is willing and able to sign an Informed Consent Form (ICF), or have a Legally Authorized Representative willing and able to consent on the patient's behalf Possess the symptoms commonly associated with PDP, e.g., hallucinations and delusions that cannot be reasonably attributed to other causes Exclusion Criteria: Patient is unwilling to participate in the non-interventional study Patient is currently participating in or is planning to participate in an investigational clinical trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1: Parkinson Disease Psychosis (PDP) patients<br>PDP patients not treated with an antipsychotic at the time of enrollment | Other: Real-world, non-interventional<br>* N/A - non-interventional<br>|
| Group 2: Parkinson Disease Psychosis (PDP) patients<br>PDP patients treated with an antipsychotic (other than NUPLAZID®) at the time of enrollment | Other: Real-world, non-interventional<br>* N/A - non-interventional<br>|
| Group 3: Parkinson Disease Psychosis (PDP) patients<br>PDP patients treated with NUPLAZID® at the time of enrollment | Other: Real-world, non-interventional<br>* N/A - non-interventional<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) | Describe the safety and effectiveness of antipsychotic therapies and other treatment approaches in the management of PDP. Describe comparative clinical, economic, and humanistic outcomes of treatment approaches for both patients and caregivers, in the context of real-world medical practice settings. | Approximately 36 months |
Establishment and Evaluation of a Post Caesarean Acute Pain Service (PCAPS)

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to compare the efficacy of analgesic methods after Caesarean Section before and after Post Caesarean Acute Pain Service establishing.

Official Title
-----------------
Establishment and Evaluation of a Post Caesarean Acute Pain Service

Conditions
-----------------
The Efficacy of Analgesic Methods After Caesarean Section

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Caesarean Section performed from October 2009 to October 2011 (study period) completed Evaluation of postoperative analgesia after Caesarean Section form. Exclusion Criteria: Not completed Standard Evaluation of postoperative analgesia after Caesarean Section form.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PRE-PCAPS<br>Parturients who underwent delivery by Caesarean Section in the period October 2009 - September 2010 | |
| POST-PCAPS<br>Parturients who underwent delivery by Caesarean Section in the period November 2010 - October 2011. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Analogue Scale (VAS) | Comparison of pain intensity (Visual Analogue Scale (VAS)) during the postoperative period (72 hours) between the two groups according to postoperative analgesic method and method of anaesthesia. | 72 hours after Caesarean Section (CS) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VAS score above 4 | unsatisfactory pain relief | 72 hours after CS | 
| Additional Analgesic Requests (AAR) Count | Comparison of the average value of the AARs count in groups in the first 72 hours after CS | 72 hours after CS | 
| Analgesia related complication Rate | Analgesia related complications including hypotension, hypertension, tachycardia, bradycardia, hypoventilation were recorded. | 72 hours after CS | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute Pain Service, postoperative analgesia, Caesarean Section, non-opioid analgesia, opioid analgesia, epidural analgesia